The effect of dulaglutide on glycated hemoglobin is associated with PNPLA3 Ι148Μ gene polymorphism in patients with type 2 diabetes mellitus.

Gavriilidis S, Andrianopoulou R, Ntenti C, Sarakapina A, Trakatelli C, Polyzos SA, Goulas A

Endocrine23 Aug 2024Cited by 4 (Europe PMC)

PMID39179734DOI10.1007/s12020-024-04007-8PepBankPUB-39179734

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

5 results from studies that gave the peptide. 5 results from people.

01HumanObservational studyEfficacy outcome
In patients with T2DM and NAFLD, HbA1c decreased after dulaglutide treatment versus baseline.
In plain wordsIn patients with diabetes and fatty liver, dulaglutide treatment was linked to lower HbA1c than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c
Study
n = 80
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg weekly · 6 monthsAs given in this study (human).
Measurements
HbA1c change
−0.72%
after treatment
Source sentences
Summary
Glycated hemoglobin (HbA1c; -0.72 ± 1.10%; p < 0.001), FLI (-5.8 ± 9.8; p < 0.001) and HSI (-1.18 ± 3.51; p = 0.004) significantly decreased after treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Relevant data from patients with inadequately controlled T2DM, also displaying NAFLD, administered 1.5 mg dulaglutide weekly for 6 months were retrospectively retrieved.
Report a problemFND-3917973401
02HumanObservational studyEfficacy outcome
In patients with T2DM and NAFLD, fatty liver index decreased after dulaglutide versus baseline.
In plain wordsIn patients with diabetes and fatty liver, dulaglutide was linked to a lower fatty liver index than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseFatty liver index
Study
n = 80
Comparator
Baseline
Outcome group
Liver fat and liver function · Liver
Studied dose
1.5 mg weekly · 6 monthsAs given in this study (human).
Measurements
FLI change
−5.8 index units
after treatment
Source sentences
Summary
Glycated hemoglobin (HbA1c; -0.72 ± 1.10%; p < 0.001), FLI (-5.8 ± 9.8; p < 0.001) and HSI (-1.18 ± 3.51; p = 0.004) significantly decreased after treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Relevant data from patients with inadequately controlled T2DM, also displaying NAFLD, administered 1.5 mg dulaglutide weekly for 6 months were retrospectively retrieved.
Report a problemFND-3917973402
03HumanObservational studyEfficacy outcome
In patients with T2DM and NAFLD, hepatic steatosis index decreased after dulaglutide versus baseline.
In plain wordsIn patients with diabetes and fatty liver, dulaglutide was linked to a lower hepatic steatosis index than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHepatic steatosis index
Study
n = 80
Comparator
Baseline
Outcome group
Liver fat and liver function · Liver
Studied dose
1.5 mg weekly · 6 monthsAs given in this study (human).
Measurements
HSI change
−1.18 index units
after treatment
Source sentences
Summary
Glycated hemoglobin (HbA1c; -0.72 ± 1.10%; p < 0.001), FLI (-5.8 ± 9.8; p < 0.001) and HSI (-1.18 ± 3.51; p = 0.004) significantly decreased after treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Relevant data from patients with inadequately controlled T2DM, also displaying NAFLD, administered 1.5 mg dulaglutide weekly for 6 months were retrospectively retrieved.
Report a problemFND-3917973403
04HumanObservational studyEfficacy outcome
In patients with T2DM and NAFLD, lipid profile improved after dulaglutide versus baseline.
In plain wordsIn patients with diabetes and fatty liver, dulaglutide was linked to an improved lipid profile compared with baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedLipid profile
Study
n = 80
Comparator
Baseline
Outcome group
Lipids · Metabolic and weight
Studied dose
1.5 mg weekly · 6 monthsAs given in this study (human).
Source sentences
Summary
Lipid profile and liver function tests also improved after treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Relevant data from patients with inadequately controlled T2DM, also displaying NAFLD, administered 1.5 mg dulaglutide weekly for 6 months were retrospectively retrieved.
Report a problemFND-3917973404
05HumanObservational studyEfficacy outcome
In patients with T2DM and NAFLD, liver function tests improved after dulaglutide versus baseline.
In plain wordsIn patients with diabetes and fatty liver, dulaglutide was linked to improved liver tests compared with baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedLiver function tests
Study
n = 80
Comparator
Baseline
Outcome group
Liver fat and liver function · Liver
Studied dose
1.5 mg weekly · 6 monthsAs given in this study (human).
Source sentences
Summary
Lipid profile and liver function tests also improved after treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Relevant data from patients with inadequately controlled T2DM, also displaying NAFLD, administered 1.5 mg dulaglutide weekly for 6 months were retrospectively retrieved.
Report a problemFND-3917973405

Studies that did not test the peptide alone4

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

06HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In dulaglutide-treated patients, CC homozygotes showed a greater HbA1c decrease than GG homozygotes, largely among women.
In plain wordsDuring dulaglutide treatment, CC genotype was linked to a greater HbA1c decrease than GG genotype, mainly in women.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c response by PNPLA3 CC genotype
Study
n: not reported in source
Comparator
GG homozygotes
Outcome group
Glycemic control · Metabolic and weight
Measurements
Relative decrease
2.4 fold
CC versus GG
Source sentences
Summary
Overall, homozygotes for the reference rs738409 allele (CC) displayed a 2.4-fold decrease (p = 0.002) and heterozygotes (CG) an 1.6-fold decrease (p = 0.013) compared to GG homozygotes after treatment, but the effect was largely limited to female patients.
2 context sentences(design, population, supporting numbers)
Summary · context
rs738409, but not rs708272, was associated with the effect of dulaglutide on HbA1c, but not on presumed hepatic steatosis or other relevant parameters.
Summary · context
Relevant data from patients with inadequately controlled T2DM, also displaying NAFLD, administered 1.5 mg dulaglutide weekly for 6 months were retrospectively retrieved.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3917973406
07HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In dulaglutide-treated patients, CG heterozygotes showed a greater HbA1c decrease than GG homozygotes, largely among women.
In plain wordsDuring dulaglutide treatment, CG genotype was linked to a greater HbA1c decrease than GG genotype, mainly in women.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c response by PNPLA3 CG genotype
Study
n: not reported in source
Comparator
GG homozygotes
Outcome group
Glycemic control · Metabolic and weight
Measurements
Relative decrease
1.6 fold
CG versus GG
Source sentences
Summary
Overall, homozygotes for the reference rs738409 allele (CC) displayed a 2.4-fold decrease (p = 0.002) and heterozygotes (CG) an 1.6-fold decrease (p = 0.013) compared to GG homozygotes after treatment, but the effect was largely limited to female patients.
2 context sentences(design, population, supporting numbers)
Summary · context
rs738409, but not rs708272, was associated with the effect of dulaglutide on HbA1c, but not on presumed hepatic steatosis or other relevant parameters.
Summary · context
Relevant data from patients with inadequately controlled T2DM, also displaying NAFLD, administered 1.5 mg dulaglutide weekly for 6 months were retrospectively retrieved.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3917973407
08HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In dulaglutide-treated patients, FLI, HSI and other relevant parameters showed no similar association with rs738409 genotype.
In plain wordsDuring dulaglutide treatment, fatty liver indices and other parameters showed no similar link to rs738409 genotype differences.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changePNPLA3 genotype associations with other parameters
Study
n: not reported in source
Comparator
Other rs738409 genotypes
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
No similar effect was observed in FLI, HSI and other relevant parameters.
2 context sentences(design, population, supporting numbers)
Summary · context
Overall, homozygotes for the reference rs738409 allele (CC) displayed a 2.4-fold decrease (p = 0.002) and heterozygotes (CG) an 1.6-fold decrease (p = 0.013) compared to GG homozygotes after treatment, but the effect was largely limited to female patients.
Summary · context
Relevant data from patients with inadequately controlled T2DM, also displaying NAFLD, administered 1.5 mg dulaglutide weekly for 6 months were retrospectively retrieved.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3917973408
09HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In dulaglutide-treated patients, rs708272 was not associated with any studied parameter.
In plain wordsDuring dulaglutide treatment, rs708272 genotype differences showed no link to the studied measurements.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeCETP genotype associations
Study
n: not reported in source
Comparator
Other rs708272 genotypes
Outcome group
Receptor activity and mechanism · Metabolic and weight
Source sentences
Summary
No association was observed between rs708272 and any of the parameters studied.
1 context sentence(design, population, supporting numbers)
Summary · context
Relevant data from patients with inadequately controlled T2DM, also displaying NAFLD, administered 1.5 mg dulaglutide weekly for 6 months were retrospectively retrieved.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3917973409

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

The effect of dulaglutide on glycated hemoglobin is associated with PNPLA3 Ι148Μ gene polymorphism in patients with type 2 diabetes mellitus.

Summary

Results from this study9

Studies that did not test the peptide alone4

Version history

Subjects

Publication types

MeSH terms

Keywords